Literature DB >> 20187195

Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity.

Benjamin M Ellingson1, Mark G Malkin, Scott D Rand, Jennifer M Connelly, Carolyn Quinsey, Pete S LaViolette, Devyani P Bedekar, Kathleen M Schmainda.   

Abstract

PURPOSE: To present comprehensive examinations of the assumptions made in functional diffusion map (fDM) analyses and provide a biological basis for fDM classification.
MATERIALS AND METHODS: Sixty-nine patients with gliomas were enrolled in this study. To determine the sensitivity of apparent diffusion coefficients (ADCs) to cellularity, cell density from stereotactic biopsy specimens was correlated with preoperative ADC maps. For definition of ADC thresholds used for fDMs, the 95% confidence intervals (CI) for changes in voxel-wise ADC measurements in normal appearing tissue was analyzed. The sensitivity and specificity to progressing disease was examined using both radiographic and neurological criteria.
RESULTS: Results support the hypothesis that ADC is inversely proportional to cell density with a sensitivity of 1.01 x 10(-7) [mm(2)/s]/[nuclei/mm(2)]. The 95% CI for white matter = 0.25 x 10(-3) mm(2)/s, gray matter = 0.31 x 10(-3) mm(2)/s, a mixture of white and gray matter = 0.40 x 10(-3) mm(2)/s, and a mixture of white matter, gray matter, and cerebrospinal fluid = 0.75 x 10(-3) mm(2)/s. Application of these measurements as ADC thresholds produce varying levels of sensitivity and specificity to disease progression, which were all significantly better than chance.
CONCLUSION: This study suggests fDMs are valid biomarkers for brain tumor cellularity.

Entities:  

Mesh:

Year:  2010        PMID: 20187195      PMCID: PMC2903058          DOI: 10.1002/jmri.22068

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  22 in total

1.  Real-time 3D image registration for functional MRI.

Authors:  R W Cox; A Jesmanowicz
Journal:  Magn Reson Med       Date:  1999-12       Impact factor: 4.668

2.  The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome.

Authors:  Bradford A Moffat; Thomas L Chenevert; Charles R Meyer; Paul E McKeever; Daniel E Hall; Benjamin A Hoff; Timothy D Johnson; Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

3.  Fractional anisotropy and tumor cell density of the tumor core show positive correlation in diffusion tensor magnetic resonance imaging of malignant brain tumors.

Authors:  Manabu Kinoshita; Naoya Hashimoto; Tetsu Goto; Naoki Kagawa; Haruhiko Kishima; Shuichi Izumoto; Hisashi Tanaka; Norihiko Fujita; Toshiki Yoshimine
Journal:  Neuroimage       Date:  2008-07-11       Impact factor: 6.556

4.  Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity.

Authors:  Y Hayashida; T Hirai; S Morishita; M Kitajima; R Murakami; Y Korogi; K Makino; H Nakamura; I Ikushima; M Yamura; M Kochi; J-i Kuratsu; Y Yamashita
Journal:  AJNR Am J Neuroradiol       Date:  2006-08       Impact factor: 3.825

5.  A quantitative model for differential motility of gliomas in grey and white matter.

Authors:  K R Swanson; E C Alvord; J D Murray
Journal:  Cell Prolif       Date:  2000-10       Impact factor: 6.831

6.  Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.

Authors:  T L Chenevert; L D Stegman; J M Taylor; P L Robertson; H S Greenberg; A Rehemtulla; B D Ross
Journal:  J Natl Cancer Inst       Date:  2000-12-20       Impact factor: 13.506

7.  Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging.

Authors:  H Lyng; O Haraldseth; E K Rofstad
Journal:  Magn Reson Med       Date:  2000-06       Impact factor: 4.668

8.  Malignant renal neoplasms: correlation between ADC values and cellularity in diffusion weighted magnetic resonance imaging at 3 T.

Authors:  G Manenti; M Di Roma; S Mancino; D A Bartolucci; G Palmieri; R Mastrangeli; R Miano; E Squillaci; G Simonetti
Journal:  Radiol Med       Date:  2008-04-02       Impact factor: 3.469

9.  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

Authors:  Anwar R Padhani; Guoying Liu; Dow Mu Koh; Thomas L Chenevert; Harriet C Thoeny; Taro Takahara; Andrew Dzik-Jurasz; Brian D Ross; Marc Van Cauteren; David Collins; Dima A Hammoud; Gordon J S Rustin; Bachir Taouli; Peter L Choyke
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

10.  Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival.

Authors:  Daniel A Hamstra; Craig J Galbán; Charles R Meyer; Timothy D Johnson; Pia C Sundgren; Christina Tsien; Theodore S Lawrence; Larry Junck; David J Ross; Alnawaz Rehemtulla; Brian D Ross; Thomas L Chenevert
Journal:  J Clin Oncol       Date:  2008-06-09       Impact factor: 44.544

View more
  113 in total

1.  Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma.

Authors:  Benjamin M Ellingson; Timothy F Cloughesy; Taryar Zaw; Albert Lai; Phioanh L Nghiemphu; Robert Harris; Shadi Lalezari; Naveed Wagle; Kourosh M Naeini; Jose Carrillo; Linda M Liau; Whitney B Pope
Journal:  Neuro Oncol       Date:  2012-01-22       Impact factor: 12.300

Review 2.  Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.

Authors:  Mark S Shiroishi; Jerrold L Boxerman; Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-09-12       Impact factor: 12.300

Review 3.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Authors:  Benjamin M Ellingson; Martin Bendszus; Jerrold Boxerman; Daniel Barboriak; Bradley J Erickson; Marion Smits; Sarah J Nelson; Elizabeth Gerstner; Brian Alexander; Gregory Goldmacher; Wolfgang Wick; Michael Vogelbaum; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Whitney B Pope; Dewen Yang; Caroline Chung; Michael V Knopp; Soonme Cha; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2015-08-05       Impact factor: 12.300

4.  Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps.

Authors:  Antonella Castellano; Marina Donativi; Roberta Rudà; Giorgio De Nunzio; Marco Riva; Antonella Iadanza; Luca Bertero; Matteo Rucco; Lorenzo Bello; Riccardo Soffietti; Andrea Falini
Journal:  Eur Radiol       Date:  2015-08-30       Impact factor: 5.315

5.  Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.

Authors:  S Mong; B M Ellingson; P L Nghiemphu; H J Kim; L Mirsadraei; A Lai; W Yong; T M Zaw; T F Cloughesy; W B Pope
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-26       Impact factor: 3.825

6.  Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma.

Authors:  Ararat Chakhoyan; Davis C Woodworth; Robert J Harris; Albert Lai; Phioanh L Nghiemphu; Linda M Liau; Whitney B Pope; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2018-05-31       Impact factor: 4.130

Review 7.  An Update on the Approach to the Imaging of Brain Tumors.

Authors:  Katherine M Mullen; Raymond Y Huang
Journal:  Curr Neurol Neurosci Rep       Date:  2017-07       Impact factor: 5.081

8.  Effects of perfusion on diffusion changes in human brain tumors.

Authors:  Alexander D Cohen; Peter S LaViolette; Melissa Prah; Jennifer Connelly; Mark G Malkin; Scott D Rand; Wade M Mueller; Kathleen M Schmainda
Journal:  J Magn Reson Imaging       Date:  2013-02-06       Impact factor: 4.813

9.  Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

Authors:  Kathleen M Schmainda; Melissa Prah; Jennifer Connelly; Scott D Rand; Raymond G Hoffman; Wade Mueller; Mark G Malkin
Journal:  Neuro Oncol       Date:  2014-01-15       Impact factor: 12.300

10.  Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.

Authors:  Vaios Hatzoglou; Jung Hun Oh; Olivia Buck; Xuling Lin; Michelle Lee; Amita Shukla-Dave; Robert J Young; Kyung K Peck; Behroze Vachha; Andrei I Holodny; Christian Grommes
Journal:  J Neurooncol       Date:  2018-08-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.